top of page
  • patricia5628

Nonprescription Intranasal Naloxone Approved by the FDA

Over the last 20 years it is estimated that over a million people have died from drug overdoses often associated with opioids. Post pandemic data indicate that opioid overdoses/deaths are increasing at a greater than previous rate and are now the leading cause of accidental death in the United States.

Today the FDA approved a nonprescription naloxone nasal spray packaged in two 4 mg doses by Emergent BioSolutions. The product should be available in pharmacies by late summer, 2023. While most States have a mechanism in place that allows pharmacists to provide treatment to at risk individuals without a personal prescription, approving an over the counter antidote will allow easier access and most definitely save lives.

10 views0 comments

Recent Posts

See All

Factors Affecting the Treatment of Chronic Pain

Chronic pain affects 25% of adults in the US and is defined as persistent pain that lasts weeks to years. Ideally identifying and treating the cause of pain is the preferred approach. When this is not

The Fourth Risk

Medications are intended to fix our medical problems but too often that isn't what happens. All medications come with side effects - some can be life threatening. 1. Adverse drug events (ADE) are unin

Naloxone - OTC

Naloxone is finally available in the US without a prescription but much more is needed to improve health outcomes among people with opioid use disorder (PWOUD). 1. Reclassification as an over-the-coun


bottom of page